Prospective Assessment of Quality of Life and Patient-Reported Toxicities Over the First Year After Chimeric Antigen Receptor T-Cell Therapy.
Hoogland AI, Barata A, Li X, Irizarry-Arroyo N, Jain MD, Welniak T, Rodriguez Y, Oswald LB, Gudenkauf LM, Chavez JC, Khimani F, Lazaryan A, Liu HD, Nishihori T, Pinilla-Ibarz J, Shah BD, Crowder SL, Parker NH, Carson TL, Vinci CE, Pidala JA, Logue J, Locke FL, Jim HSL.
Hoogland AI, et al.
Transplant Cell Ther. 2024 Sep 19:S2666-6367(24)00666-3. doi: 10.1016/j.jtct.2024.09.013. Online ahead of print.
Transplant Cell Ther. 2024.
PMID: 39306278